Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.

Related Articles

Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.

Bioorg Med Chem. 2017 Apr 05;:

Authors: Zhao Y, Zhang J, Zhuang R, He R, Xi J, Pan X, Shao Y, Pan J, Sun J, Cai Z, Liu S, Huang W, Lv X

Abstract
In this study, a series of novel pyridine and pyrimidine-containing derivatives were designed, synthesized and biologically evaluated for their c-Met inhibitory activities. In the biological evaluation, half of the target compounds exhibited moderate to potent c-Met inhibitory activities. Among which, it is noteworthy that compounds 13d not only showed most potent c-Met inhibitory potency but also displayed excellent anti-proliferative activity (IC50=127nM against EBC-1 cell line) as well as an acceptable kinase selectivity profile. Moreover, the western blot assay indicated that 13d inhibited c-Met phosphorylation in EBC-1 cells in a dose-dependent manner, with complete abolishment at 0.1mM. All these experimental results suggested that 13d could be served as a promising lead compound for the development of anticancer agents.

PMID: 28412159 [PubMed - as supplied by publisher]

http://ift.tt/2oOHQFo